دورية أكاديمية
Association of dengue infection with anti-alpha-gal antibodies, IgM, IgG, IgG1, and IgG2.
| العنوان: | Association of dengue infection with anti-alpha-gal antibodies, IgM, IgG, IgG1, and IgG2. |
|---|---|
| المؤلفون: | Olajiga OM; Department of Entomology, Kansas State University, Manhattan, KS, United States., Maldonado-Ruiz LP; Department of Entomology, Kansas State University, Manhattan, KS, United States., Fatehi S; Department of Entomology, Kansas State University, Manhattan, KS, United States., Cardenas JC; Laboratorio Clínico, Hospital Local Los Patios, Los Patios, Norte de Santander, Colombia., Gonzalez MU; Laboratorio Clinico, Empresa Social Del Estado Hospital Emiro Quintero Cañizares, Ocaña, Norte de Santander, Colombia., Gutierrez-Silva LY; Laboratorio Clínico, Hospital Erasmo Meoz, Cúcuta, Norte de Santander, Colombia., Londono-Renteria B; Department of Entomology, Kansas State University, Manhattan, KS, United States.; School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, United States., Park Y; Department of Entomology, Kansas State University, Manhattan, KS, United States. |
| المصدر: | Frontiers in immunology [Front Immunol] 2022 Oct 14; Vol. 13, pp. 1021016. Date of Electronic Publication: 2022 Oct 14 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Dengue Virus* , Dengue*, Animals ; Humans ; Immunoglobulin G ; Immunoglobulin M ; Antibodies, Viral ; Galactose ; Primates ; Mammals |
| مستخلص: | Dengue virus (DENV) transmitted by the Aedes mosquitoes is the etiological agent of dengue fever, one of the fastest-growing reemerging mosquito-borne diseases on the planet with a 30-fold surge in the last five decades. Interestingly, many arthropod-borne pathogens, including DENV type 2, have been reported to contain an immunogenic glycan galactose-alpha1,3-galactose (alpha-Gal or aGal). The aGal molecule is a common oligosaccharide found in many microorganisms and in most mammals, except for humans and the Old-World primates. The loss of aGal in humans is considered to be an evolutionary innovation for enabling the production of specific antibodies against aGal that could be presented on the glycan of pathogens. The objective of this study was to evaluate different anti-aGal antibodies (IgM, IgG, IgG1, and IgG2) in people exposed to DENV. We observed a significant difference in anti-aGal IgG and IgG1 levels among dengue severity classifications. Furthermore, a significant positive correlation was observed between the anti-aGal IgG and the number of days with dengue symptoms in patients. Additionally, both anti-aGal IgM and IgG levels differ between the two geographical locations of patients. While the anti-aGal IgM and IgG2 levels were not significantly different according to the dengue severity levels, age was negatively correlated with anti-aGal IgM and positively correlated with anti-aGal IgG2. Significant involvement of aGal antibodies in Dengue infection processes is suggested based on the results. Our results open the need for further studies on the exact roles and the mechanisms of the aGal antibodies in Dengue infection. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Olajiga, Maldonado-Ruiz, Fatehi, Cardenas, Gonzalez, Gutierrez-Silva, Londono-Renteria and Park.) |
| References: | Cancer Sci. 2013 Mar;104(3):282-90. (PMID: 23240661) PLoS Negl Trop Dis. 2020 Jan 16;14(1):e0007831. (PMID: 31945061) Cell. 2014 Dec 4;159(6):1277-89. (PMID: 25480293) Am J Trop Med Hyg. 2012 Oct;87(4):584-93. (PMID: 23042846) Sci Bull Sci Found Philipp. 2015 Apr;60(7):661-664. (PMID: 26640300) Front Immunol. 2022 Mar 04;13:844262. (PMID: 35309294) ACS Cent Sci. 2017 Nov 22;3(11):1140-1142. (PMID: 29202015) Exp Mol Med. 2017 Mar 10;49(3):e301. (PMID: 28280265) Nat Microbiol. 2019 Sep;4(9):1508-1515. (PMID: 31182801) Soc Sci Med. 2005 Jul;61(2):495-502. (PMID: 15893062) PLoS One. 2013;8(2):e55566. (PMID: 23390540) Trop Med Infect Dis. 2020 Oct 03;5(4):. (PMID: 33022908) ACS Cent Sci. 2017 Sep 27;3(9):1026-1031. (PMID: 28979944) Front Immunol. 2020 Jun 16;11:1055. (PMID: 32655548) Parasit Vectors. 2021 Jun 5;14(1):303. (PMID: 34090497) Nat Rev Microbiol. 2018 Aug;16(8):508-518. (PMID: 29777177) Virol J. 2012 Mar 09;9:64. (PMID: 22405440) Turk J Med Sci. 2019 Apr 18;49(2):497-505. (PMID: 30997788) Front Cell Infect Microbiol. 2020 Nov 03;10:574417. (PMID: 33224897) PLoS One. 2015 Jul 24;10(7):e0132122. (PMID: 26208004) Biochim Biophys Acta. 2008 Feb;1780(2):75-88. (PMID: 18047841) Arch Gerontol Geriatr. 1984 Jul;3(2):175-88. (PMID: 6476977) J Immunol. 1991 Apr 1;146(7):2394-400. (PMID: 1706399) Front Immunol. 2017 Dec 04;8:1733. (PMID: 29255472) Acta Trop. 2021 Dec;224:106136. (PMID: 34555353) Nature. 1996 Jan 4;379(6560):85-8. (PMID: 8538747) Mem Inst Oswaldo Cruz. 2019;114:e190145. (PMID: 31291383) Front Cell Infect Microbiol. 2020 Oct 22;10:572681. (PMID: 33194810) J Virol. 2009 May;83(9):4338-44. (PMID: 19244332) Front Immunol. 2019 May 31;10:1210. (PMID: 31214181) Parasit Vectors. 2018 Nov 14;11(1):594. (PMID: 30428923) J Exp Med. 1984 Nov 1;160(5):1519-31. (PMID: 6491603) Front Immunol. 2013 May 16;4:114. (PMID: 23720661) Proc Natl Acad Sci U S A. 2020 Feb 11;117(6):3319-3325. (PMID: 31974303) J Biol Chem. 1991 Oct 25;266(30):20244-61. (PMID: 1939085) NPJ Vaccines. 2019 Mar 22;4:13. (PMID: 30911415) Science. 2017 Nov 17;358(6365):929-932. (PMID: 29097492) Mol Biochem Parasitol. 1990 Feb;39(1):101-7. (PMID: 2106074) J Immunol. 1989 Apr 15;142(8):2828-34. (PMID: 2467941) Immunology. 2020 Sep;161(1):66-79. (PMID: 32583419) PLoS One. 2019 Jan 2;14(1):e0208455. (PMID: 30601814) Oncoimmunology. 2012 Sep 1;1(6):924-929. (PMID: 23162760) Vaccines (Basel). 2020 Apr 24;8(2):. (PMID: 32344637) Vaccines (Basel). 2020 Jan 09;8(1):. (PMID: 31936588) Sci Rep. 2018 Sep 21;8(1):14224. (PMID: 30242261) |
| معلومات مُعتمدة: | P20 GM103638 United States GM NIGMS NIH HHS; P30 GM145499 United States GM NIGMS NIH HHS; R21 AI163423 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: Alpha-gal (α -gal); antibodies; dengue (DENV); flaviviral infection; vector-borne disease (VBD) |
| المشرفين على المادة: | 0 (Immunoglobulin G) 0 (Immunoglobulin M) 0 (Antibodies, Viral) X2RN3Q8DNE (Galactose) |
| تواريخ الأحداث: | Date Created: 20221031 Date Completed: 20221101 Latest Revision: 20230406 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC9614307 |
| DOI: | 10.3389/fimmu.2022.1021016 |
| PMID: | 36311743 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2022.1021016 |